MEETING WITH REPRESENTATIVES OF EIGER BIOPHARMACEUTICALS, INC.
Today, President of Mongolia Khaltmaagiin Battulga met representatives of U.S. based Eiger BioPharmaceuticals, Inc., including David A. Cory, President and CEO, Ingrid Choong, Vice President of Investor Relations and Corporate Development, and John Ferraro, Vice President of Clinical Operations. Eiger BioPharmaceuticals is implementing the Phase 3 of its lead program which focuses on developing a treatment for the Hepatitis Delta Virus (HDV) infection.
The company has been working with Mongolian doctors, especially the Onom Foundation, which is committed to liver diseases, for the last 11 years. The company representatives spoke about this cooperation with the President, while exchanging views on the necessity to introduce the treatment of HDV infection and the situation surrounding liver diseases.
Mr. Cory noted the importance of conducting research and creating the conditions for introduction of the treatment of HDV infection in Mongolia, as well as preventing the infection, and requested attention on this matter on all levels.
President Battulga discussed the matter of affordability of the treatment and expressed his commitment to reducing the high prevalence of liver cirrhosis and cancer deaths in Mongolia.